USPTO serial 98403934
VORWARTS PHARMA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 11, 2025
- Examiner
- KEAM, ALEX S
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with VORWARTS PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Diana Portna
2435 Bedford street Unit 12bStamford, CT 06905United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Acai powder dietary supplements; Acaricides; Adjuvants for medical purposes; Albumin dietary supplements; Alginate dietary supplements; Amino acids for medical purposes; Anaesthetics; Analgesics; Anthelmintics; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antibiotics; Antiparasitic preparations; Antiseptics; Appetite suppressant pills; Bacterial preparations for medical and veterinary use; Bacteriological preparations for medical and veterinary use; Cardiovascular pharmaceuticals; Casein dietary supplements; Cellulose esters for pharmaceutical purposes; Charcoal for pharmaceutical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of erectile dysfunction, for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, for the treatment of diabetes, for the treatment of cardiovascular and cerebrovascular diseases, for the treatment of anaphylactic reactions;; Dietary supplements with a cosmetic effect; Digestives for pharmaceutical purposes; Enzyme dietary supplements; Enzyme preparations for medical purposes; Ferments for pharmaceutical purposes; Food supplements, namely, anti-oxidants; Glycerine for medical purposes; Haemoglobin; Herbal extracts, other than essential oils, for medical purposes; Infant formula; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Injectable pharmaceuticals for treatment of anaphylactic reactions; Lecithin dietary supplements; Medical preparations for slimming purposes; Medicated candies; Medicinal preparations for the treatment of erectile dysfunction, for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, for the treatment of diabetes, for the treatment of cardiovascular and cerebrovascular diseases, for the treatment of anaphylactic reactions; Mineral dietary supplements; Nutraceuticals for the treatment of erectile dysfunction, ocular disorders or diseases, bacteria-based diseases, diabetes, cardiovascular and cerebrovascular diseases, anaphylactic reactions; Nutraceuticals for use as a dietary supplement; Nutritional supplements; Ocular pharmaceuticals; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of rectile dysfunction, ocular disorders or diseases, bacteria-based diseases, diabetes, cardiovascular and cerebrovascular diseases, anaphylactic reactions; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Propolis dietary supplements; Propolis for pharmaceutical purposes; Protein dietary supplements; Vaginal washes for medical purposes; Vermifuges; Vitamin preparations; Wheat germ dietary supplements; Yeast dietary supplements; Yeast for pharmaceutical purposes | ACTIVE | Feb 1, 2024 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 11, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 11, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 21, 2025 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Oct 21, 2025 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Oct 18, 2025 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Oct 18, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 15, 2025 | IUAF | USE AMENDMENT FILED | — |
| May 15, 2025 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Dec 24, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 12, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 12, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 23, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 3, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 2, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 25, 2024 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jun 25, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 13, 2024 | NWAP | NEW APPLICATION ENTERED | — |